Cryoport and VGXI Partner for Cell and Gene Therapy Supply Chain Solutions

• Cryoport and VGXI announced a strategic partnership to enhance biopharmaceutical supply chain support for cell and gene therapies, including mRNA-based treatments.

• Partnership operations will commence in October 2024, offering biostorage and bioservices from Cryoport’s Houston facility.

Cryoport, Inc. has announced a new strategic partnership with VGXI, Inc., aimed at bolstering supply chain services for biopharmaceutical companies developing cell and gene therapies, as well as mRNA-based treatments. The collaboration will leverage Cryoport’s biostorage and bioservices to manage VGXI’s plasmid DNA products, which are manufactured at VGXI’s facilities in The Woodlands and Conroe, Texas. Operations are scheduled to begin in October 2024.

This partnership combines VGXI’s capabilities in nucleic acid biopharmaceuticals with Cryoport’s integrated supply chain solutions. Cryoport will offer storage, shipping services, data solutions, and other bioservices to ensure the efficient delivery of plasmid DNA products to VGXI’s end customers.

Jerrell Shelton, CEO of Cryoport, emphasised the alignment of both companies’ goals: “Being chosen by VGXI as a partner for biostorage and bioservices underscores our shared commitment to quality and innovation. Together, we will provide biopharmaceutical companies a comprehensive and integrated solution to support clinical programs that are developing lifesaving, next-generation therapeutic modalities.”

The partnership supports growing demand in the advanced therapy market, enabling secure storage and transport of plasmid DNA, which is essential for gene therapies, DNA vaccines, and other treatments. Young Park, CEO of VGXI, stated, “Choosing Cryoport as our trusted partner further elevates our mission by ensuring safe, secure, and world-class storage and transport of these assets.”